Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials

被引：13
|
作者：
Gyawali, B. [1 ]
Ando, Y. [1 ]
机构：
[1] Nagoya Univ, Grad Sch Med, Dept Clin Oncol & Chemotherapy, Nagoya, Aichi, Japan
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷 / 04期
关键词：
D O I：
10.1093/annonc/mdw667
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：898 / 899
页数：2
相关论文
共 50 条
  • [31] Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis
    George, Daniel J.
    Martini, Jean-Francois
    Staehler, Michael
    Motzer, Robert J.
    Magheli, Ahmed
    Donskov, Frede
    Escudier, Bernard
    Li, Sherry
    Casey, Michelle
    Valota, Olga
    Laguerre, Brigitte
    Pantuck, Allan J.
    Pandha, Hardev S.
    Patel, Anup
    Lechuga, Maria
    Ravaud, Alain
    CLINICAL CANCER RESEARCH, 2019, 25 (04) : 1165 - 1173
  • [32] Immunotherapy vs sunitinib as first-line treatment for advanced renal cell carcinoma in favourable risk patients: A meta-analysis of randomized clinical trials
    Manneh Kopp, R.
    Lema Medina, M.
    Ibata, L.
    Martinez, S.
    De Velasco, G.
    Castellano Gauna, D.
    ANNALS OF ONCOLOGY, 2021, 32 : S699 - S699
  • [33] Adjuvant Therapy in High-Risk Renal Cell Cancer: A Systematic Review and Meta-analysis
    Riaz, Irbaz B.
    Faridi, Warda
    Husnain, Muhammad
    Malik, Saad Ullah
    Sipra, Qurat Ul Ain R.
    Gondal, Farva R.
    Xie, Hao
    Yadav, Siddhartha
    Kohli, Manish
    MAYO CLINIC PROCEEDINGS, 2019, 94 (08) : 1524 - 1534
  • [34] A systematic review and combined analysis of phase III trials to evaluate the safety of adjuvant sunitinib in patients with high risk renal cell carcinoma after nephrectomy.
    Quirch, Miguel
    Thein, Kyaw Zin
    Ball, Somedeb
    Adhikari, Nimesh
    Jones, Catherine
    D'Cunha, Nicholas C.
    Awasthi, Sanjay
    Tijani, Lukman Aderoju
    Hardwicke, Fred L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (34)
  • [35] Re: Adjuvant Immunotherapy in Renal Cell Carcinoma: A Systematic Review and Meta-analysis
    Riveros, C.
    Huang, E.
    Ranganathan, S.
    JOURNAL OF UROLOGY, 2023, 210 (05): : 820 - 821
  • [36] Risk of primary progressive disease with tyrosine kinase inhibitors sorafenib and sunitinib in patients with renal cell carcinoma: A meta-analysis
    Su, X.
    Ranpura, V.
    Wu, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [37] Exploring Biological Predictive Factors of Progression After Surgery in High-Risk Renal Cell Carcinoma: Results From the French Cohort of the Randomized S-TRAC Trial Patients
    Ouzaid, Idir
    Kammerer-Jacquet, Solene Florence
    Khene, Zineddine
    Ravaud, Alain
    Patard, Jean-Jacques
    Bensalah, Karim
    Rioux-Leclercq, Nathalie
    FRONTIERS IN SURGERY, 2020, 7
  • [38] Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: Exploratory pharmacogenomic analysis.
    George, Daniel J.
    Martini, Jean-Francois
    Staehler, Michael D.
    Chang, Yen-Hwa
    Breza, Jan
    Patard, Jean-Jacques
    Motzer, Robert J.
    Magheli, Ahmed
    Carteni, Giacomo
    Donskov, Frede
    Escudier, Bernard
    Li, Sherry
    Casey, Michelle
    Valota, Olga
    Laguerre, Brigitte
    Pantuck, Allan J.
    Pandha, Hardev S.
    Patel, Anup
    Lechuga, Mariajose
    Ravaud, Alain
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [39] Discontinuation of adjuvant sunitinib due to adverse events in patients with high-risk renal cell carcinoma after nephrectomy: A combined analysis of phase III trials.
    Ball, Somedeb
    Thein, Kyaw Zin
    Quirch, Miguel
    Adhikari, Nimesh
    D'Cunha, Nicholas C.
    Jones, Catherine
    Hardwicke, Fred L.
    Awasthi, Sanjay
    Tijani, Lukman
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (34)
  • [40] Adjuvant therapy in high-risk renal cell cancer: A systematic review and cumulative meta-analysis
    Siddiqi, Rabbia
    Bin Riaz, Irbaz
    Islam, Mahnoor
    Sipra, Qurat Ul Ain Riaz
    Ryu, Alexander J.
    Raina, Ammad
    Murad, M. Hassan
    Kohli, Manish
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345